Strategic acquisition Sherlock Biosciences was acquired by OraSure Technologies in 2024, signaling potential cross-sell opportunities for OraSure’s point-of-need and home diagnostic products to Sherlock’s network and customers.

Global manufacturing footprint Expansion into a UK biomanufacturing facility in 2023 suggests capacity for regional production capabilities; approach to customers with needs for scalable CRISPR-based diagnostics and decentralized testing solutions.

CRISPR diagnostic platform Focused on CRISPR-based diagnostics and ai-enabled Dx development tools present opportunities to offer integrated testing workflows, data analytics, and streamlined regulatory-ready solutions to biotech and healthcare providers.

Public funding momentum Past USDA SBIR funding and other grants indicate receptiveness to collaboration and funded R&D programs; target government, academic, and industry partners seeking co-development and subsidy-aligned projects.

Mid-market growth potential Revenue in the mid-range with a lean team implies strong efficiency and flexibility; sales strategies can emphasize rapid deployment, partner-led sales, and tiered service offerings to clinics, labs, and regional health networks.